The B2B platform for the best purchasing descision. Identify and compare relevant B2B manufacturers, suppliers and retailers
Filter
Locations
Result types
Type of company
Select company type
Industries
Select industry
Company status
Select company status preset
Number of employees
Min.
Max.
Founding year
3D Printing and Bioprinting Research Lab
Belfast, United Kingdom
11-50 Employees
-
We provide consultancy and training services for industry, academics and scholars. Committed to quality research, training, consultancy, and contract R&D. Please browse our site to get a better idea of who we are and what we do. Our lab offers honest, impartial advice & best-in-class solutions. Our studies include: conceptualization, formulation / manufacturing, physicochemical characterization using state-of-the-art techniques, Regulatory & Quality analysis, computational modelling, in vivo, ex vivo, and in vitro evaluation. Our Lab, has been recognised by Expertscape as world leaders in 3D Printing. Cardiovascular diseases constitute a number of conditions which are the leading cause of death globally. Examples of Lab Press Mentions in Additive Manufacturing.
Core business
WELCOME TO THE 3D PRINTING & BIOPRINTING STATE-OF-THE-ART LAB
... in 3D Printing & Bioprinting for drug delivery and tissue ...
Inventia Life
Sydney, Australia
11-50 Employees
2013
We develop solutions to create advanced cell models and help forward-thinking pioneers in the fields of drug discovery and biomedical research to create human tissue for research and therapy. This physiological complexity offers an environment in which world-class research and discovery can occur, right in your own lab. We are backed by leading venture capital firms and incredibly thankful for the support. Through innovative technology and strong partnerships, Inventia Skin will drive a paradigm shift in personalised clinical therapies for skin trauma.
Product
This is not your average approach to 3D bioprinting.
... technology in digital bioprinting is built for fast, scalable and ...
Cellink
Gothenburg, Sweden
251-500 Employees
2016
We develop technologies that democratize 3D bioprinting – providing the leading researchers in the world the tools they need to create the future of health. Our goal was to make high-quality bioinks readily available for researchers. Today we are industry leaders in the 3D bioprinting space. At CELLINK, we are proud of our many nationalities spanning 5 offices around the globe. CELLINK is proud to be a part of the BICO family – a collection of the leading life science companies tethered around the principle of bioconvergence, who are bringing disruptive solutions to the entire life science industry. We are organized into three business areas: Biosciences, Bioautomation, and Bioprinting. Our products aim to reduce the organ shortage and speed up drug development by providing accessible life science solutions that combine biology and technology, fundamentally shifting the global healthcare industry. Our products are used in a number of industries and sectors by leaders in their respective fields all around the world.
Product
Online Course: Introduction to Bioprinting
... Introduction to Bioprinting Online Course - Covers the basics of ...
3D MATTERS LIMITED
Cambridge, United Kingdom
1-10 Employees
2016
At 3D Matters Limited we work with organisations to deliver the best 3D printers on the market capable of producing parts in ceramic and metal materials. Whilst 3D Matters is primarily a technology hardware and materials provider, we do offer project support in the form of our 3D printing services. Thereafter we provide 3D printers for sale with all the necessary hardware and associated services for installing these 3D printers into our customer's organisation. Above all our aim is to enable our clients to design and manufacture more quickly and cost effectively. Therefore decreasing the product design cycle and time to market.
Product
Bioprinting and Laboratory Research
... Bioprinting and Laboratory Research • 3D ...
Poietis
Pessac, France
11-50 Employees
2014
Poietis is a biotechnology company specialized in the development and manufacturing of human tissues by 4D bioprinting. The bioprinting technology of Poietis, whose company is licensed exclusively and worldwide, is the result of an innovative research conducted for ten years by Inserm and the University of Bordeaux. Before joining Poietis, Bertrand worked 10 years at Mauna Kea Technologies (listed company based in Paris) as R&D Manager to develop the most miniaturized microscope in the world dedicated to medical imaging in vivo. Poietis mission is to provide solutions leveraging a proprietary, innovative Next-Generation Bioprinting platform and bring Tissue Engineering therapies to patients. Poietis is a spin-off from INSERM and University of Bordeaux where Laser-Assisted Bioprinting Technology was initially developed. Poietis brings to the market two bioprinters based on Next-Generation Bioprinting platform. On the basis of its expertise in bioprinting technologies and in particular high resolution laser bioprinting, Poietis has also developed the multimodal bioprinting platform NGB (« Next Generation Bioprinting »). Besides the NGB-R commercial bioprinter dedicated to R&D, the compagny is developing the NGB-C system for clinical applications.
Core business
Poietis - Poietis - 4D Bioprinting | Next Generation Bioprinting
... where Laser-Assisted Bioprinting Technology was initially developed. ...
ONS BIO
Solon, United States
1-10 Employees
2019
Our goal is to help researchers get answers to the biological questions quickly by outsourcing their workload to us. ONS BIO was founded in with the following goals. ONS BIO is an authorized distributor for all Logos Biosystems products in US Midwest region. GeneAb™ is a registered trademark of Genomeme Canada. ONS BIO is an authorized distributor for all Genomeme RUO products in US. Introducing - ROKIT Healthcare delivers an effective, customized regenerative therapy for treating deep, non-healing wounds by using autologous solutions with their disruptive technology. High quality yet affordable products for application in your life sciences research. ONS BIO offers proteomics, metabolomics, glycomics, and bioinformatics analysis services to researchers in the pharmaceutical, biotechnology, agriculture and nutrition industries, as well as academic and government organizations.
Core business
BIOPRINTING
... For all your 3D Bioprinting, Bioinks and Life science research needs. We ...
Quantis Biotechnology
-
- Employees
-
Our purpose is to be the edge of innovation, delivering a new generation of human and biocompatible biomaterials to revolutionize biomedical research and medical devices. By developing the first ever human biomaterials through our patented bioprocess, we are now searching for potential partners to develop together with us new medical devices and applications using our human collagen matrix.
Product
3D BIOPRINTING
... Biotechnology uses bioprinting, bioengineering and innovation to ...
Collplant
Rishon LeZion, Israel
11-50 Employees
1981
CollPlant is a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing. Our mission at CollPlant is to deliver ground-breaking products for regenerative medicine that offer the optimal treatment options to patients. Our Vision: Be the leaders in regenerative medicine, helping people live longer and better through our innovative collagen technology. CollPlant’s rhCollagen offers numerous opportunities in medical aesthetics, such as regenerative dermal fillers and breast implants. CollPlant's regenerative aesthetics products are currently under development. Leveraging on the unique properties of rhCollagen and biomaterial know-how, we are developing a pipeline of products aimed at 3D bioprinting of tissues and organs and medical aesthetics. Leveraging on the unique properties of our BioInks and biomaterial know-how, we are developing a pipeline of products aimed at 3D bioprinting of tissues and organs and medical aesthetics. Collink.3DTM is a BioInk platform based on recombinant human collagen for use in 3D bioprinting, accurately mimicking the physical properties of human tissues and organs.
Core business
3D Bioprinting: Organ & Tissue Manufacturing
... 3D Bioprinting: Organ & Tissue ...
Frontier Bio
Oakland, United States
1-10 Employees
2018
We're creating engineered tissues to replace animal studies and save lives. Join us at the Forefront of Tissue Engineering & Regenerative Medicine. Animal experimentation is both controversial and unreliable in providing human-relevant results. But traditional 2D cell culture of human cells fails to capture the complexity of the 3D cellular microenvironment. Made of living human cells, our vascular Blood Vessel Mimics (BVMs) are already being used for medical device testing.
Core business
Enhanced with Bioprinting
... using cutting-edge 3D bioprinting, organ-on-a-chip, and organoid ...
Foldink 3D Bioprinting
Yerevan, Armenia
1-10 Employees
2017
Foldink is a biotech company focused on spreading 3D bioprinting technology globally. We develop and create bioinks, bioprinters, and other relevant equipment and materials for the benefit of biomedical scientists worldwide. Today, Foldink stands as a diverse, international team uniting entrepreneurial minds, accomplished research specialists, skilled engineers, savvy marketers, and a robust scientific and business advisory board. At Foldink, we are dedicated to making a tangible difference in the world by pioneering advancements that have the potential to transform countless lives. Founded in 2018 and officially incorporated as Foldink Corp. Ask our support team if you have any questions about your product. Embrace the future of bioprinting with our modular bioprinters, engineered to bring your visionary designs to life with precision and efficiency. Unleash a new era of scientific breakthroughs with Foldink, and unfold the limitless possibilities of Bioprinting.
Core business
What is bioprinting? (simplified)
... Our aim is to make 3D Bioprinting Technology available all over the ...
Technologies which have been searched by others and may be interesting for you:
Some interesting numbers and facts about your company results for Bioprinting
| Country with most fitting companies | United States |
| Amount of fitting manufacturers | 1390 |
| Amount of suitable service providers | 1176 |
| Average amount of employees | 11-50 |
| Oldest suiting company | 2007 |
| Youngest suiting company | 2022 |
20%
40%
60%
80%
Bioprinting is an innovative method of using 3D printing technology to fabricate tissue and organ constructs by precisely layering cells, growth factors, and biomaterials. This process relies on computer-guided pipettes to deposit layers of living cells, along with a biocompatible scaffold, to create structures that mimic natural tissues. The significance of bioprinting in the medical and scientific communities is profound, offering potential breakthroughs in regenerative medicine, pharmaceutical research, and tissue engineering. It enables researchers to produce more accurate human tissue models for drug testing, reducing the reliance on animal models and accelerating the development of new therapeutics. Furthermore, bioprinting holds the promise of revolutionizing transplant medicine by providing a potential source of functional organs tailored to individual patients, effectively addressing the critical shortage of donor organs worldwide. By facilitating the creation of complex tissue structures with precise cellular architecture, bioprinting not only advances our understanding of tissue development and disease pathology but also paves the way for personalized medicine, where treatments and interventions can be customized to the unique biological makeup of each patient. The impact of bioprinting extends beyond the laboratory and into the realm of actual patient care, marking a significant step forward in the convergence of technology, biology, and health care.
1. Personalization and Precision
Bioprinting allows for the creation of tissues and organs that are specifically tailored to the patient's anatomy and medical needs. This personalization enhances the compatibility and effectiveness of implants or grafts, reducing the risk of rejection and improving recovery times.
2. Reduced Waiting Times for Transplants
With the ability to print biological materials, bioprinting presents a promising solution to the shortage of organ donors. By potentially providing organs on demand, this technology could significantly reduce waiting times for transplant patients, saving countless lives.
3. Innovation in Drug Testing
Bioprinted tissues offer a more accurate platform for drug testing compared to traditional methods. By using human tissues that mimic the conditions of living organs, researchers can obtain more relevant data on the effects of new drugs, speeding up the development process and enhancing safety.
4. Cost Efficiency
Over time, bioprinting could become more cost-effective than traditional organ transplant methods. By reducing the need for donor matching and long hospital stays due to complications, bioprinting has the potential to lower healthcare costs significantly.
While evaluating the different suppliers make sure to check the following criteria:
1. Print Resolution and Precision
The ability of the bioprinter to produce fine details, crucial for tissue engineering and complex tissue constructs.
2. Compatibility with Bioinks
Ensure the supplier offers bioprinters that are compatible with a wide range of bioinks, providing flexibility in research and application.
3. Printing Speed
The speed at which the bioprinter operates without compromising the quality and viability of the printed structures.
4. Software and User Interface
Look for intuitive software that simplifies the design and printing process, making it accessible for users with varying levels of expertise.
5. After-Sales Support and Warranty
Consider suppliers that provide comprehensive after-sales support, including training, maintenance, and warranty services to ensure long-term reliability and performance.
6. Scalability and Upgrade Options
The ability to upgrade the bioprinter as new technologies and capabilities emerge, ensuring longevity and adaptability of the investment.
Bioprinting technology has found significant application in the pharmaceutical industry, primarily for drug testing and development. This innovative approach allows for the creation of 3D printed tissues that closely mimic human organs, providing a more accurate platform for testing drug efficacy and safety before proceeding to clinical trials. By reducing the reliance on animal testing, bioprinting not only accelerates the drug development process but also enhances the ethical aspects of research. In the field of regenerative medicine, bioprinting plays a crucial role in developing tissue and organ transplants. By utilizing patients' cells, bioprinters can create tissues that are biocompatible and significantly reduce the risk of rejection. This technology is paving the way for personalized medicine, where treatments and transplants are tailor-made to match the specific needs and genetic makeup of the individual patient. The cosmetic industry also benefits from bioprinting technology, especially in product testing and development. Companies can use bioprinted skin models to evaluate the effects of cosmetics on human skin, ensuring safety and efficacy. This method offers a more ethical and scientifically accurate alternative to animal testing, aligning with the growing consumer demand for cruelty-free products. Bioprinting is revolutionizing the research and development sector across multiple industries by providing innovative solutions for drug testing, regenerative medicine, and cosmetic product development. Its ability to create complex, three-dimensional biological structures offers unprecedented opportunities for advancement in healthcare and consumer goods.
Bioprinting, a pioneering technology at the forefront of medical research and tissue engineering, currently hovers around a Technology Readiness Level (TRL) of 4 to 5. This classification stems from its successful demonstration in controlled environments, where bioprinters have been able to fabricate complex three-dimensional structures from living cells with a degree of precision and reproducibility. However, the reason it has not progressed to higher TRLs lies in several technical challenges. Key among these is the difficulty in vascularizing printed tissues, a critical step for creating larger, functional organs that can survive and integrate within the human body. Additionally, replicating the intricate cellular architecture of natural tissues presents a significant hurdle, as does ensuring the long-term viability and function of printed constructs. While advancements in biomaterials and printing technologies continue to push the boundaries of what's possible, the leap from printing small tissue constructs to fully functional organs requires overcoming these complex biological and engineering challenges. These technical barriers underscore the current TRL positioning of bioprinting, reflecting its stage of development as an innovative yet still maturing technology within the biomedical field.
In the Short-Term, bioprinting is set to focus significantly on enhancing precision in cell placement and the viability of printed tissues. Advances in bio-inks, which are crucial for supporting cells post-printing, are expected to see improvements in terms of biocompatibility and mechanical properties. This phase will likely witness the first wave of 3D-printed skin for cosmetic testing, reducing animal testing and speeding up product development cycles. The Mid-Term development of bioprinting is anticipated to expand beyond tissues to the creation of functional organs for transplant. The integration of stem cells into bioprinting processes will play a pivotal role, aimed at producing organs that are not only structurally accurate but also fully functional. This period is expected to see the emergence of bioprinted liver and kidney tissues for pharmaceutical testing, significantly impacting the speed and safety of drug development. In the Long-Term, the vision for bioprinting includes the routine clinical application of bioprinted organs for transplantation, drastically reducing the dependency on donor organs. Breakthroughs in vascularization techniques will be critical to ensure these organs are viable long-term. Additionally, the customization of organs to match patient-specific needs could become a reality, offering personalized healthcare solutions and significantly improving outcomes in transplant medicine.
Some interesting questions that has been asked about the results you have just received for Bioprinting
What are related technologies to Bioprinting?
Based on our calculations related technologies to Bioprinting are Biomedical (Red), Bioinformatics (Gold), Environmental Biotechnology (Grey), Agricultural Biotechnology (Green), Food Related Biotechnology (Yellow)
Who are Start-Ups in the field of Bioprinting?
Start-Ups who are working in Bioprinting are Smart Tissues, orthoprint mfg
Which industries are mostly working on Bioprinting?
The most represented industries which are working in Bioprinting are Biotechnology, Other, Manufacturing, Printing, Medical
How does ensun find these Bioprinting Companies?
ensun uses an advanced search and ranking system capable of sifting through millions of companies and hundreds of millions of products and services to identify suitable matches. This is achieved by leveraging cutting-edge technologies, including Artificial Intelligence.
